Goodwin Procter advised MacroGenics on its exclusive collaboration and license agreement with Zai Lab to develop and commercialize Margetuximab, MGD013 and TRIDENT™ molecule in greater China….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
